Charles D. Lopez

4.1k total citations
97 papers, 1.8k citations indexed

About

Charles D. Lopez is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Charles D. Lopez has authored 97 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 28 papers in Cancer Research and 27 papers in Molecular Biology. Recurrent topics in Charles D. Lopez's work include Pancreatic and Hepatic Oncology Research (43 papers), Cancer Genomics and Diagnostics (24 papers) and Cancer-related Molecular Pathways (16 papers). Charles D. Lopez is often cited by papers focused on Pancreatic and Hepatic Oncology Research (43 papers), Cancer Genomics and Diagnostics (24 papers) and Cancer-related Molecular Pathways (16 papers). Charles D. Lopez collaborates with scholars based in United States, Germany and Spain. Charles D. Lopez's co-authors include Vishwanath R. Lingappa, C. Spencer Yost, Stanley B. Prusiner, Louie Naumovski, Zhiyi Zhu, Dexi Chen, Zhiyong Yu, R Myers, Brett C. Sheppard and Kerstin Maria Kampa-Schittenhelm and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Charles D. Lopez

92 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles D. Lopez United States 23 1.0k 987 375 223 201 97 1.8k
Ingrid Hedenfalk Sweden 28 824 0.8× 1.1k 1.1× 852 2.3× 285 1.3× 387 1.9× 78 2.4k
Zhen Zhao United States 17 745 0.7× 1.5k 1.5× 382 1.0× 130 0.6× 365 1.8× 34 2.4k
Andrei Turtoï France 27 580 0.6× 1.1k 1.1× 483 1.3× 246 1.1× 312 1.6× 64 1.9k
Hong Sug Kim South Korea 26 621 0.6× 1.5k 1.5× 428 1.1× 209 0.9× 349 1.7× 36 1.9k
Diarmuid Moran United States 20 471 0.5× 468 0.5× 168 0.4× 417 1.9× 66 0.3× 47 1.4k
Mu-Yan Cai China 33 735 0.7× 1.7k 1.8× 965 2.6× 473 2.1× 237 1.2× 58 2.9k
Natasha G. Deane United States 15 918 0.9× 1.3k 1.4× 461 1.2× 273 1.2× 450 2.2× 22 2.3k
Gloria Peiró Spain 26 644 0.6× 737 0.7× 519 1.4× 181 0.8× 116 0.6× 64 1.7k

Countries citing papers authored by Charles D. Lopez

Since Specialization
Citations

This map shows the geographic impact of Charles D. Lopez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles D. Lopez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles D. Lopez more than expected).

Fields of papers citing papers by Charles D. Lopez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles D. Lopez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles D. Lopez. The network helps show where Charles D. Lopez may publish in the future.

Co-authorship network of co-authors of Charles D. Lopez

This figure shows the co-authorship network connecting the top 25 collaborators of Charles D. Lopez. A scholar is included among the top collaborators of Charles D. Lopez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles D. Lopez. Charles D. Lopez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mira, Jose L., Jessica Minnier, Benjamin R. Kingston, et al.. (2025). Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Science Translational Medicine. 17(785). eadq3110–eadq3110. 14 indexed citations
2.
Rivero, Jaydira Del, et al.. (2024). Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications. Current Problems in Cancer. 52. 101131–101131. 1 indexed citations
3.
Parappilly, Michael, Brett S. Walker, Alice Fung, et al.. (2024). Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences. 25(17). 9198–9198. 1 indexed citations
4.
Parappilly, Michael, Emile Latour, Lei Wang, et al.. (2024). Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Cancers. 16(21). 3650–3650.
5.
Ciardiello, Fortunato, Yung‐Jue Bang, Andrés Cervantes, et al.. (2023). Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results. Cancer Medicine. 12(12). 13145–13154. 6 indexed citations
6.
7.
8.
Lopez, Charles D., Adel Kardosh, Shaun M. Goodyear, et al.. (2023). Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 41(4_suppl). TPS772–TPS772. 2 indexed citations
9.
Chen, Emerson Y., Adel Kardosh, Nima Nabavizadeh, et al.. (2023). Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine. 12(12). 12986–12995. 3 indexed citations
10.
11.
Hecht, J. Randolph, Sara Lonardi, Johanna C. Bendell, et al.. (2021). Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). Journal of Clinical Oncology. 39(10). 1108–1118. 78 indexed citations
12.
Fend, Falko, et al.. (2021). ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Frontiers in Molecular Biosciences. 8. 727203–727203. 3 indexed citations
13.
Sutton, Thomas L., Kevin G. Billingsley, Brett S. Walker, et al.. (2020). Detection Of Tumor Multifocality In Resectable Intrahepatic Cholangiocarcinoma: Defining The Optimal Pre-Operative Imaging Modality. HPB. 22. S45–S46. 1 indexed citations
14.
Allen-Petersen, Brittany L., Tyler Risom, Zipei Feng, et al.. (2018). Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Research. 79(1). 209–219. 62 indexed citations
15.
Zarour, Luai, John Swain, Kevin G. Billingsley, et al.. (2018). Use of circulating cancer cell hybrids to monitor treatment response to hepatic arterial infusion in patients with colorectal cancer metastatic to the liver. HPB. 20. S352–S352. 1 indexed citations
16.
Zarour, Luai, Sudarshan Anand, Kevin G. Billingsley, et al.. (2017). Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular and Molecular Gastroenterology and Hepatology. 3(2). 163–173. 198 indexed citations
17.
Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2016). FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. 2(1). 1–8. 8 indexed citations
18.
Wang, Zhiping, Dexi Chen, Zhiyi Zhu, et al.. (2016). ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival. Biochemical and Biophysical Research Communications. 482(4). 1271–1277. 10 indexed citations
19.
Schittenhelm, Marcus M., et al.. (2013). Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure. PLoS ONE. 8(11). e80193–e80193. 18 indexed citations
20.
Lopez, Charles D., et al.. (2002). Inhibition of cell death by ribosomal protein L35a. Cancer Letters. 180(2). 195–202. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingrid Hedenfalk Breakdown of academic impact, for papers by Zhen Zhao Breakdown of academic impact, for papers by Andrei Turtoï Breakdown of academic impact, for papers by Hong Sug Kim Breakdown of academic impact, for papers by Diarmuid Moran Breakdown of academic impact, for papers by Mu-Yan Cai Breakdown of academic impact, for papers by Natasha G. Deane Breakdown of academic impact, for papers by Gloria Peiró
Rankless by CCL
2026